NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders and life-threatening pulmonary conditions. The company entered public markets through a merger with Big Rock Partners Acquisition Corp, the blank-check vehicle that served as its SPAC sponsor and completed its initial public offering in 2018. A Form 10-Q filed on May 15, 2019, bearing accession number 0001654954-19-006096, reflects an early period in the company's SEC reporting history within the healthcare and specialty pharmaceuticals sector. The de-SPAC transaction positioned NRXP as a publicly traded clinical-stage issuer navigating FDA development pathways. Sign up at SpacDesk for complete filing timelines, sponsor profiles, and deal analytics covering NRXP and the full SPAC universe.